1. Home
  2. NVAX vs NVCR Comparison

NVAX vs NVCR Comparison

Compare NVAX & NVCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Novavax Inc.

NVAX

Novavax Inc.

N/A

Current Price

$10.60

Market Cap

1.7B

Sector

Health Care

ML Signal

N/A

Logo NovoCure Limited

NVCR

NovoCure Limited

N/A

Current Price

$15.92

Market Cap

2.0B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
NVAX
NVCR
Founded
1987
2000
Country
United States
Switzerland
Employees
749
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Medical/Dental Instruments
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.7B
2.0B
IPO Year
1996
2015

Fundamental Metrics

Financial Performance
Metric
NVAX
NVCR
Price
$10.60
$15.92
Analyst Decision
Buy
Buy
Analyst Count
9
7
Target Price
$14.00
★ $27.14
AVG Volume (30 Days)
★ 4.4M
881.8K
Earning Date
11-05-2026
10-29-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 309.76
21.79
EPS
★ N/A
N/A
Revenue
★ $1,123,479,000.00
$655,353,000.00
Revenue This Year
N/A
$10.76
Revenue Next Year
N/A
$10.88
P/E Ratio
★ N/A
N/A
Revenue Growth
★ 64.69
8.28
52 Week Low
$6.20
$9.82
52 Week High
$11.85
$21.45

Technical Indicators

Market Signals
Indicator
NVAX
NVCR
Relative Strength Index (RSI) 66.82 47.89
Support Level $8.42 $14.93
Resistance Level $10.85 $18.43
Average True Range (ATR) 0.51 0.57
MACD 0.03 -0.02
Stochastic Oscillator 85.83 60.84

Price Performance

Historical Comparison
NVAX
NVCR

About NVAX Novavax Inc.

Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, an in-house early-stage R&D business to build a pipeline of high-value assets using its technology along with seeking to enter into partnerships to drive value creation for its assets.

About NVCR NovoCure Limited

NovoCure Ltd is an oncology company with a proprietary platform technology in the United States. Its business involves the development, manufacture, and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis, and other products and technologies for the treatment of Glioblastoma, Non-small cell lung cancer, and Pancreatic cancer. Geographically, the company derives the majority of its revenue from the United States and the rest from Germany, Japan, and other markets.

Share on Social Networks: